

2 December 2025

Futura Medical plc

("Futura", "the Company" or "the Group")

Result of General Meeting and Total Voting Rights

Futura Medical (AIM:FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that following the General Meeting held earlier today at the Company's registered offices at 10 a.m., all resolutions set out in the notice of General Meeting contained in the Circulated dated 13 November 2025 were duly passed.

Resolutions 1 and 3 were proposed as ordinary resolutions and resolutions 2, 4 and 5 were proposed as special resolutions. The total number of votes received on each resolution were as follows:

	For		Against			
Resolution	Votes For	% of votes cast	Votes Against	% of votes cast	Votes withheld	Total votes cast
1	154,316,685	99.23	1,203,457	0.77	198,143	155,718,285
2	154,329,985	99.23	1,200,657	0.77	187,643	155,718,285
3	154,316,685	99.23	1,203,457	0.77	198,143	155,718,285
4	154,316,485	99.23	1,203,657	0.77	198,143	155,718,285
5	154,314,875	99.23	1,205,267	0.77	198,143	155,718,285

Accordingly, all conditions precedent relating to the proposed placing and subscription (the **"Fundraise"**) announced on 13 November 2025 have now been met (save for Subsequent Admission).

Application has been made for 13,200,000 Subscription Shares and 231,800,000 Conditional Placing Shares to be admitted to trading on AIM, it is expected that the admission will become effective and that dealings will commence at 8.00 a.m. on or around 4 December 2025.

Total Voting Rights

Following the Admission, the Company will have 581,120,659 ordinary shares of £0.002 each in issue.

The Company does not hold any shares in treasury and all of the Ordinary Shares have equal voting rights. Therefore, the figures above represent the total voting rights in the Company and this figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the voting rights of the Company under the FCA's Disclosure Guidance and Transparency Rules

Unless otherwise stated, capitalised terms not otherwise defined in the text of this announcement have the same meanings ascribed to them as in the announcement released by the Company on 13 November 2025.

- ENDS -

For further information, please contact:

Futura Medical plc Alex Duggan CEO Angela Hildreth FD/COO	+44 (0) 1483 685 670
Panmure Liberum - Nominated Adviser Will Goode / Emma Earl /Mark Rogers	+44 (0) 20 3100 2000
Turner Pope Investments (TPI) Ltd - Broker	+44 (0) 20 3657 0050

Guy McDougall / Andrew Thacker	+44 (0) 20 3007 0000
Alma Strategic Communications	+44 (0)20 3405 0205
Rebecca Sanders-Hewett	
Sam Modlin	futura@almastrategic.com

About Futura Medical plc

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMZZMGZMZVGKZM